Immunodermatology News

The FDA has approved rituximab for the treatment of adult patients with moderate-to-severe pemphigus vulgaris, a rare autoimmune blistering disease that affects the skin and mucous membranes, according to a company press release.

BOSTON — Rheumatologists, gastroenterologists, dermatologists, immunologists and other health care providers who care for patients with immune-mediated inflammatory diseases will gather at the Interdisciplinary Autoimmune Summit in Boston this weekend for a collaborative discussion of treatment strategies.

The FDA has rejected approval of Celltrion’s biologics license applications for Truxima, a proposed rituximab biosimilar, and Herzuma, a proposed trastuzumab biosimilar, issuing Complete Response Letters for both products.

Myeloablative autologous stem cell transplantation improved long-term clinical outcomes, including overall survival and event-free survival, among patients with diffuse cutaneous systemic sclerosis, according to findings published in the New England Journal of Medicine.

One patient in a large cohort of individuals with autoimmune blistering diseases developed pneumocystis pneumonia, suggesting that routine prophylaxis of this condition may not be warranted in this patient population, according to recent findings.

Enanthemas were commonly reported among patients with non-classic forms of pityriasis rosea, including persistent and pediatric forms of the disease.

This week, Genentech announced its phase 3 trial of Actemra for patients with systemic sclerosis has completed enrollment. The study will compare the drug’s safety and efficacy with placebo in patients with systemic sclerosis, according to a press release.

Study results reporting that nail findings distinguished patients with psoriatic arthritis from those with psoriasis without arthritis was among the top read articles in July on Healio.com/Dermatology.

Patients with lung cancer who were received immunotherapy experienced hair repigmentation, with the majority also experiencing good clinical response, according to recently published study results in JAMA Dermatology.

Study results showing minimal to no transfer of Cimzia from mother's plasma to breast milk was a top-read article of the past week on Healio.com/Dermatology.